Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Philadelphia, Pennsylvania

CNS medication trials in Philadelphia, PA

59 CNS medication studies are recruiting participants at sites in Philadelphia as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Philadelphia at a glance

  • 59 studies are recruiting at a site in Philadelphia.
  • By phase: Early Phase 1 (4), Phase 1 (2), Phase 1/2 (2), Phase 2 (13), Phase 3 (31), Phase 4 (6), No phase (1). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (45), university, hospital or other (11), government (3).
  • By research area: Depression (16), Parkinson's Disease (13), Migraine (10), Epilepsy (9), Schizophrenia (6), ADHD (2), Multiple Sclerosis (2), Bipolar Disorder (1).
  • Most recent update to one of these records: November 17, 2026.

Depression studies recruiting in Philadelphia

Basic details from each study's public record (the 30 most recently updated of 59). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study sites
    Adams Clinical Philadelphia · Flourish Research Philadelphia
    Registry record
    NCT06793397 · updated
  2. Precision Depression Adalimumab Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Daniel Moriarity
    Study site
    University of Pennsylvania
    Registry record
    NCT07845604 · updated
  3. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    University of Pennsylvania
    Registry record
    NCT07002034 · updated
  4. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Study site
    Adams Clinical Philadelphia
    Registry record
    NCT07592689 · updated
  5. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Penn Medicine: University of Pennsylvania Health System
    Registry record
    NCT07412756 · updated
  6. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    University of Pennsylvania - Perelman School of Medicine
    Registry record
    NCT05850689 · updated
  7. Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University of Pennsylvania
    Registry record
    NCT06559306 · updated
  8. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University of Pennsylvania
    Registry record
    NCT07573176 · updated
  9. A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study sites
    Adams Clinical Philadelphia · Penn Medicine: University of Pennsylvania Health System
    Registry record
    NCT07775300 · updated
  10. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06966401 · updated
  11. Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
    Registry record
    NCT07226232 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Schizophrenia studies recruiting in Philadelphia

  1. A Study to Evaluate the Effect of KarXT on Urological Safety

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Adams Clinical Philadelphia
    Registry record
    NCT07221877 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Philadelphia

  1. A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Penn Medicine: University of Pennsylvania Health System
    Registry record
    NCT07286175 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Philadelphia

  1. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Hospital of the University of Pennsylvania ( Site 5007)
    Registry record
    NCT06952504 · updated
  2. A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Honickman Center ( Site 5033)
    Registry record
    NCT07216703 · updated
  3. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06989112 · updated
  4. An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

    • Phase 2
    • Ages 50 to 80
    • All sexes
    Sponsor
    Yale University
    Study site
    University of Pennsylvania
    Registry record
    NCT06996652 · updated
  5. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    University Pennsylvania Hospital
    Registry record
    NCT07174310 · updated
  6. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    Thomas Jefferson University Hospital
    Registry record
    NCT06680830 · updated
  7. KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Abramson Cancer Center of the University of Pennsylvania ( Site 0010)
    Registry record
    NCT04165070 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Philadelphia

  1. A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Celgene
    Study site
    Thomas Jefferson University, Jefferson Headache Center
    Registry record
    NCT06782490 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Epilepsy studies recruiting in Philadelphia

  1. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Registry record
    NCT07563881 · updated
  2. Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

    • Phase 3
    • Ages 4 to 55
    • All sexes
    Sponsor
    SK Life Science, Inc.
    Study site
    Children's Hospital of Philadelphia
    Registry record
    NCT05219617 · updated
  3. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    University of Pennsylvania
    Registry record
    NCT05667142 · updated
  4. ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

    • Phase 1/2
    • Ages 2 to 12
    • All sexes
    Sponsor
    Ionis Pharmaceuticals, Inc.
    Study site
    The Children's Hospital of Philadelphia (CHOP)
    Registry record
    NCT07531745 · updated
  5. A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

    • Phase 3
    • Ages 2 and older
    • All sexes
    Sponsor
    Epygenix
    Study site
    The Children's Hospital of Philadelphia
    Registry record
    NCT04462770 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Migraine studies recruiting in Philadelphia

  1. Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

    • Phase 4
    • Ages 18 to 70
    • All sexes
    Sponsor
    Mayo Clinic
    Study site
    University of Pennsylvania
    Registry record
    NCT06972056 · updated
  2. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Clinical Research Philadelphia
    Registry record
    NCT07645924 · updated
  3. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Clinical Research Philadelphia
    Registry record
    NCT07674654 · updated
  4. Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Clario
    Registry record
    NCT04649242 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Ask about studies near Philadelphia

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call